A composition patent protecting combinations of Biotec Pharmacon’s proprietary compound soluble yeast beta-glucan (SBG) as an adjuvant together with monoclonal antibodies for trea...
Biotec Phamacon will present its report for Q1 2010 on May 11th at 09:00. The presentation will be held at Thon Conference Vika Atrium, Oslo.
The presentation will also be avai...
The Board of Directors has today given notice of ordinary general meeting in Biotec Pharmacon to be held May 4th, 2010, at 15:00. The meeting will be held at the company's premises...
Biotec Marine Biochemicals reviewed in PCR Insider - the leading journal for PCR users
Published 09.04.2010
The review focuses on the strong technological platform of Biotec Marine Biochemicals and the obvious advantages the products offer to the customers. Focus is also given to the exp...
Svein Lien appointed new CEO of Biotec Pharmacon ASA
Published 10.03.2010
Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 1...
Biotec Pharmacon presenting re-established platform at BIO-Europe 2010
Published 09.03.2010
Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Se...
Testing SBG packaging containers after weak results from oral mucositis study
Published 22.02.2010
Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays in...
Biotec Pharmacon to focus on bio-pharmaceuticals - sells Immunocorp Consumer Health AS
Published 30.12.2009
Biotec Pharmacon ASA has reached an agreement on the sale of its wholly-owned subsidiaries Immunocorp Consumer Health AS and Immunocorp Inc. USA to the Norwegian company Sana Pharm...
Biotec Pharmacon realigns strategy and reduces workforce
Published 11.12.2009
Biotec Pharmacon has decided to reduce the workforce within the parent company by 20 people out of a total of 35, to reflect a reduced activity level following the negative outcome...
